MTD · Mettler Toledo International Inc/
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EPS non-GAAP | $20.35 | Six Months Ended June 30, 2026 | — |
|
|
|||
| Adjusted free cash flow non-GAAP | $366,720K | Six Months Ended June 30, 2026 | -58.2% |
|
|
|||
| Adjusted Operating Profit non-GAAP | $309.3M | Q2 2026 | — |
|
|
|||
| Local Currency Sales Growth non-GAAP | 6% | Q2 2026 | — |
|
|
|||
| Local Currency Sales Growth excluding acquisitions non-GAAP | 4% | Q2 2026 | — |
|
|
|||
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MTD
this stock
Mettler Toledo International Inc/
|
$28.62B | +1.6% | +4.0% | 32.2 | 3.9% |
|
TMO
Thermo Fisher Scientific Inc.
|
$212.35B | -0.8% | +0.4% | 30.9 | 1.4% |
|
DHR
Danaher Corp /De/
|
$137.07B | -14.5% | +8.5% | 34.6 | 1.4% |
|
IDXX
Idexx Laboratories Inc /De
|
$44.10B | -17.4% | +10.4% | 41.1 | 2.7% |
|
IQV
Iqvia Holdings Inc.
|
$39.22B | +4.3% | +41.6% | 29.2 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MTD | +6.7% | +8.2% | +3.1% | +10.9% | +1.6% |
| SPY | +1.1% | +0.3% | +8.2% | +0.0% | +9.6% |
| vs SPY | +5.6% | +7.9% | -5.1% | +10.8% | -8.0% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.